- Home
- LDWY vs GTBP Comparison
LDWY vs GTBP Comparison
Compare LDWY & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LDWY | GTBP |
|---|---|---|
| Founded | 1990 | 1965 |
| Country | United States | United States |
| Employees | 160 | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2M | 2.6M |
| IPO Year | 1991 | N/A |
Fundamental Metrics
Financial Performance| Metric | LDWY | GTBP |
|---|---|---|
| Price | $3.54 | $0.83 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 55.0K | ★ 1.5M |
| Earning Date | 11-10-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.70 | N/A |
| Revenue | ★ $69,769,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.98 | ★ N/A |
| Revenue Growth | ★ 121.91 | N/A |
| 52 Week Low | $3.11 | $0.54 |
| 52 Week High | $6.19 | $4.10 |
Technical Indicators
Market Signals| Indicator | LDWY | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 46.61 | 61.63 |
| Support Level | $3.20 | $0.63 |
| Resistance Level | $3.45 | $0.75 |
| Average True Range (ATR) | 0.30 | 0.06 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 25.60 | 89.81 |
Price Performance
Historical ComparisonAbout LDWY Lendway Inc. (DE)
Lendway Inc is a specialty agricultural and finance company focused on making and managing its ag investments in the United States and internationally. The company operates in industries: Specialty Ag, consisting of the Bloomia business.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.